| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 34 | 2024 | 349 | 4.750 |
Why?
|
| Neurology | 4 | 2021 | 113 | 2.180 |
Why?
|
| Nervous System Diseases | 6 | 2021 | 500 | 1.770 |
Why?
|
| Spinal Muscular Atrophies of Childhood | 5 | 2022 | 21 | 1.550 |
Why?
|
| Neuromyelitis Optica | 7 | 2023 | 26 | 1.320 |
Why?
|
| Muscular Atrophy, Spinal | 3 | 2022 | 45 | 1.060 |
Why?
|
| Pediatrics | 5 | 2021 | 1141 | 1.010 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 2 | 2018 | 7 | 0.790 |
Why?
|
| Child | 62 | 2024 | 29154 | 0.770 |
Why?
|
| Neuromuscular Diseases | 1 | 2020 | 63 | 0.730 |
Why?
|
| Hypoglossal Nerve Diseases | 1 | 2019 | 5 | 0.710 |
Why?
|
| Myelitis, Transverse | 4 | 2016 | 13 | 0.690 |
Why?
|
| HLA-DRB1 Chains | 6 | 2024 | 82 | 0.680 |
Why?
|
| Biological Products | 1 | 2022 | 274 | 0.670 |
Why?
|
| Meningitis | 1 | 2019 | 112 | 0.660 |
Why?
|
| Headache | 1 | 2019 | 163 | 0.650 |
Why?
|
| Disabled Children | 1 | 2018 | 26 | 0.630 |
Why?
|
| Neurodevelopmental Disorders | 2 | 2021 | 413 | 0.620 |
Why?
|
| Hypertrophy | 2 | 2019 | 162 | 0.580 |
Why?
|
| Plasma Exchange | 1 | 2018 | 117 | 0.580 |
Why?
|
| Adolescent | 42 | 2023 | 31252 | 0.570 |
Why?
|
| Motor Neuron Disease | 1 | 2016 | 16 | 0.560 |
Why?
|
| RNA-Binding Protein FUS | 1 | 2016 | 26 | 0.550 |
Why?
|
| Cerebellar Ataxia | 3 | 2023 | 72 | 0.550 |
Why?
|
| Muscular Dystrophies | 3 | 2023 | 51 | 0.540 |
Why?
|
| Child, Preschool | 32 | 2023 | 16273 | 0.540 |
Why?
|
| Internship and Residency | 3 | 2021 | 1375 | 0.530 |
Why?
|
| Telemedicine | 1 | 2021 | 471 | 0.520 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2023 | 5539 | 0.510 |
Why?
|
| Gene-Environment Interaction | 4 | 2023 | 166 | 0.510 |
Why?
|
| Pituitary Diseases | 1 | 2014 | 18 | 0.500 |
Why?
|
| Disease Progression | 8 | 2023 | 6682 | 0.480 |
Why?
|
| Lymphocytosis | 1 | 2014 | 58 | 0.480 |
Why?
|
| Humans | 97 | 2024 | 261506 | 0.450 |
Why?
|
| Infant | 22 | 2021 | 13310 | 0.450 |
Why?
|
| Opsoclonus-Myoclonus Syndrome | 2 | 2023 | 2 | 0.450 |
Why?
|
| Phosphotransferases (Phosphomutases) | 1 | 2012 | 3 | 0.450 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 671 | 0.440 |
Why?
|
| Leukodystrophy, Globoid Cell | 1 | 2012 | 5 | 0.440 |
Why?
|
| Demyelinating Diseases | 3 | 2023 | 77 | 0.430 |
Why?
|
| Immunosuppressive Agents | 5 | 2023 | 1375 | 0.430 |
Why?
|
| Phaeohyphomycosis | 2 | 2022 | 12 | 0.430 |
Why?
|
| Congenital Disorders of Glycosylation | 1 | 2012 | 37 | 0.420 |
Why?
|
| Muscular Dystrophies, Limb-Girdle | 2 | 2023 | 24 | 0.420 |
Why?
|
| Encephalitis | 3 | 2023 | 143 | 0.420 |
Why?
|
| Fatigue | 1 | 2018 | 1239 | 0.400 |
Why?
|
| Exome | 2 | 2016 | 1239 | 0.390 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2020 | 2291 | 0.390 |
Why?
|
| Optic Nerve Diseases | 1 | 2012 | 103 | 0.380 |
Why?
|
| Male | 62 | 2023 | 123000 | 0.380 |
Why?
|
| Oligonucleotides | 2 | 2022 | 227 | 0.350 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2024 | 489 | 0.330 |
Why?
|
| Brain Diseases | 2 | 2023 | 403 | 0.330 |
Why?
|
| Female | 57 | 2023 | 141928 | 0.330 |
Why?
|
| Muscle Weakness | 3 | 2016 | 116 | 0.300 |
Why?
|
| Rituximab | 3 | 2022 | 1528 | 0.290 |
Why?
|
| Quality of Life | 2 | 2018 | 4532 | 0.290 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 2 | 2017 | 35 | 0.290 |
Why?
|
| Recurrence | 8 | 2023 | 4758 | 0.280 |
Why?
|
| Infant, Newborn | 7 | 2022 | 8223 | 0.280 |
Why?
|
| Neurodegenerative Diseases | 2 | 2021 | 264 | 0.280 |
Why?
|
| Movement Disorders | 2 | 2014 | 232 | 0.280 |
Why?
|
| Cognitive Dysfunction | 2 | 2022 | 333 | 0.280 |
Why?
|
| Immunologic Factors | 2 | 2021 | 649 | 0.280 |
Why?
|
| Vitamin D | 2 | 2019 | 261 | 0.270 |
Why?
|
| Autoimmune Diseases of the Nervous System | 2 | 2023 | 29 | 0.270 |
Why?
|
| Alleles | 5 | 2021 | 2437 | 0.270 |
Why?
|
| Autoantibodies | 6 | 2023 | 576 | 0.270 |
Why?
|
| Intellectual Disability | 3 | 2023 | 1032 | 0.270 |
Why?
|
| Environmental Exposure | 2 | 2018 | 288 | 0.260 |
Why?
|
| Cognition Disorders | 2 | 2022 | 786 | 0.260 |
Why?
|
| Mitochondrial Myopathies | 2 | 2020 | 28 | 0.260 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2023 | 7702 | 0.250 |
Why?
|
| Aquaporin 4 | 4 | 2023 | 15 | 0.250 |
Why?
|
| Mutation | 11 | 2023 | 15179 | 0.250 |
Why?
|
| Age of Onset | 7 | 2023 | 827 | 0.250 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2007 | 274 | 0.240 |
Why?
|
| Case-Control Studies | 11 | 2023 | 6100 | 0.240 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2022 | 223 | 0.240 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 2 | 2023 | 132 | 0.240 |
Why?
|
| Cerebral Palsy | 1 | 2005 | 63 | 0.240 |
Why?
|
| Myoclonic Epilepsies, Progressive | 1 | 2023 | 13 | 0.240 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2005 | 165 | 0.230 |
Why?
|
| Myoclonus | 1 | 2023 | 34 | 0.230 |
Why?
|
| Kinesis | 1 | 2003 | 2 | 0.230 |
Why?
|
| Isoxazoles | 1 | 2004 | 81 | 0.230 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 4 | 2023 | 38 | 0.230 |
Why?
|
| Muscular Dystrophy, Duchenne | 2 | 2016 | 69 | 0.230 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 4320 | 0.220 |
Why?
|
| Diagnosis, Differential | 9 | 2021 | 4744 | 0.220 |
Why?
|
| Cerebral Ventriculitis | 1 | 2022 | 13 | 0.220 |
Why?
|
| Neural Conduction | 2 | 2020 | 112 | 0.220 |
Why?
|
| Central Nervous System Infections | 1 | 2022 | 19 | 0.220 |
Why?
|
| Dystonic Disorders | 1 | 2023 | 81 | 0.210 |
Why?
|
| Microcephaly | 3 | 2013 | 325 | 0.210 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2022 | 33 | 0.210 |
Why?
|
| Muscular Diseases | 1 | 2023 | 161 | 0.210 |
Why?
|
| B7-2 Antigen | 1 | 2022 | 55 | 0.210 |
Why?
|
| Electromyography | 2 | 2020 | 226 | 0.210 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2016 | 473 | 0.210 |
Why?
|
| Spasms, Infantile | 1 | 2004 | 165 | 0.210 |
Why?
|
| Gait Ataxia | 1 | 2021 | 5 | 0.210 |
Why?
|
| Ocular Motility Disorders | 1 | 2022 | 47 | 0.210 |
Why?
|
| Muscular Dystrophy, Emery-Dreifuss | 1 | 2021 | 10 | 0.210 |
Why?
|
| Ozone | 1 | 2022 | 33 | 0.200 |
Why?
|
| Dystonia | 1 | 2023 | 163 | 0.200 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2021 | 11 | 0.200 |
Why?
|
| Diplopia | 1 | 2021 | 66 | 0.200 |
Why?
|
| Aniridia | 1 | 2021 | 17 | 0.200 |
Why?
|
| Injection Site Reaction | 1 | 2021 | 9 | 0.200 |
Why?
|
| Myopathy, Central Core | 1 | 2020 | 6 | 0.200 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2021 | 55 | 0.200 |
Why?
|
| Gain of Function Mutation | 1 | 2022 | 126 | 0.200 |
Why?
|
| Vertebral Artery Dissection | 1 | 2000 | 6 | 0.190 |
Why?
|
| Brain Abscess | 1 | 2021 | 60 | 0.190 |
Why?
|
| Migraine with Aura | 1 | 2021 | 17 | 0.190 |
Why?
|
| Cohort Studies | 8 | 2021 | 9244 | 0.190 |
Why?
|
| Cerebellum | 1 | 2005 | 449 | 0.190 |
Why?
|
| Hemiplegia | 1 | 2021 | 47 | 0.190 |
Why?
|
| Neurologists | 1 | 2020 | 19 | 0.190 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2020 | 10 | 0.190 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2021 | 49 | 0.190 |
Why?
|
| Central Nervous System Diseases | 1 | 2021 | 129 | 0.190 |
Why?
|
| Glycine-tRNA Ligase | 1 | 2020 | 7 | 0.190 |
Why?
|
| Survival of Motor Neuron 1 Protein | 1 | 2020 | 21 | 0.190 |
Why?
|
| Anticonvulsants | 1 | 2004 | 431 | 0.180 |
Why?
|
| Hashimoto Disease | 1 | 2020 | 19 | 0.180 |
Why?
|
| Phenotype | 9 | 2023 | 6295 | 0.180 |
Why?
|
| Cat-Scratch Disease | 1 | 2020 | 35 | 0.180 |
Why?
|
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2020 | 26 | 0.180 |
Why?
|
| Accreditation | 1 | 2020 | 126 | 0.180 |
Why?
|
| Myositis | 1 | 2020 | 79 | 0.180 |
Why?
|
| Introns | 1 | 2021 | 432 | 0.180 |
Why?
|
| Myasthenia Gravis | 1 | 2021 | 99 | 0.180 |
Why?
|
| Genetic Association Studies | 2 | 2021 | 1084 | 0.180 |
Why?
|
| Echocardiography | 2 | 2016 | 1182 | 0.180 |
Why?
|
| Infant, Premature | 1 | 2005 | 787 | 0.180 |
Why?
|
| Glucocorticoids | 3 | 2021 | 629 | 0.180 |
Why?
|
| Retrospective Studies | 13 | 2023 | 37905 | 0.180 |
Why?
|
| Seizures | 4 | 2023 | 989 | 0.180 |
Why?
|
| Anaphylaxis | 1 | 2021 | 119 | 0.180 |
Why?
|
| Microarray Analysis | 1 | 2020 | 392 | 0.170 |
Why?
|
| Migraine Disorders | 1 | 2000 | 79 | 0.170 |
Why?
|
| Brain | 8 | 2021 | 4113 | 0.170 |
Why?
|
| Education, Special | 1 | 2018 | 8 | 0.170 |
Why?
|
| Immunoglobulin G | 4 | 2022 | 1021 | 0.170 |
Why?
|
| Disabled Persons | 1 | 2020 | 121 | 0.170 |
Why?
|
| Spinal Cord | 3 | 2015 | 690 | 0.170 |
Why?
|
| Communicable Diseases | 2 | 2020 | 193 | 0.170 |
Why?
|
| Mutation, Missense | 4 | 2021 | 1152 | 0.170 |
Why?
|
| Chromosome Deletion | 2 | 2014 | 1005 | 0.160 |
Why?
|
| United States | 11 | 2020 | 15433 | 0.160 |
Why?
|
| Syndrome | 5 | 2023 | 1351 | 0.160 |
Why?
|
| Risk Factors | 12 | 2024 | 17523 | 0.160 |
Why?
|
| Membrane Proteins | 2 | 2021 | 2819 | 0.160 |
Why?
|
| Long-Term Care | 1 | 2018 | 83 | 0.160 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 332 | 0.160 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2020 | 233 | 0.160 |
Why?
|
| West Nile Fever | 1 | 2020 | 151 | 0.160 |
Why?
|
| Rehabilitation | 1 | 2018 | 46 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 402 | 0.160 |
Why?
|
| Child Health Services | 1 | 2018 | 82 | 0.150 |
Why?
|
| Filamins | 1 | 2017 | 33 | 0.150 |
Why?
|
| Immune System Diseases | 1 | 2018 | 65 | 0.150 |
Why?
|
| Muscle Hypotonia | 2 | 2016 | 180 | 0.150 |
Why?
|
| Family | 2 | 2021 | 736 | 0.150 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2019 | 4549 | 0.150 |
Why?
|
| Ataxia | 3 | 2023 | 176 | 0.150 |
Why?
|
| Disease Susceptibility | 2 | 2017 | 538 | 0.150 |
Why?
|
| Biopsy | 3 | 2021 | 3443 | 0.150 |
Why?
|
| Abnormalities, Multiple | 2 | 2014 | 998 | 0.150 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 698 | 0.150 |
Why?
|
| Recovery of Function | 1 | 2020 | 703 | 0.150 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2022 | 1555 | 0.140 |
Why?
|
| Developmental Disabilities | 2 | 2018 | 674 | 0.140 |
Why?
|
| Adjuvants, Immunologic | 1 | 2020 | 657 | 0.140 |
Why?
|
| Neutropenia | 1 | 2021 | 968 | 0.140 |
Why?
|
| Encephalomyelitis, Acute Disseminated | 3 | 2015 | 15 | 0.140 |
Why?
|
| Young Adult | 11 | 2021 | 21445 | 0.140 |
Why?
|
| Atrophy | 2 | 2008 | 261 | 0.140 |
Why?
|
| Calcium Channels | 1 | 2017 | 197 | 0.140 |
Why?
|
| Neuroblastoma | 1 | 2022 | 686 | 0.140 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2016 | 37 | 0.140 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 403 | 0.140 |
Why?
|
| Dietary Fats | 1 | 2017 | 339 | 0.130 |
Why?
|
| Hydroxymethyl and Formyl Transferases | 1 | 2015 | 4 | 0.130 |
Why?
|
| Rhabdomyolysis | 1 | 2016 | 52 | 0.130 |
Why?
|
| Ultrasonography, Interventional | 1 | 2018 | 429 | 0.130 |
Why?
|
| Patient-Centered Care | 1 | 2018 | 294 | 0.130 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 849 | 0.130 |
Why?
|
| Sequence Analysis, DNA | 2 | 2020 | 2483 | 0.130 |
Why?
|
| Child Day Care Centers | 1 | 2014 | 24 | 0.130 |
Why?
|
| Heart Conduction System | 1 | 2016 | 165 | 0.130 |
Why?
|
| Lambert-Eaton Myasthenic Syndrome | 1 | 2014 | 12 | 0.120 |
Why?
|
| Hypersensitivity | 1 | 2017 | 216 | 0.120 |
Why?
|
| Prednisone | 2 | 2021 | 984 | 0.120 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 369 | 0.120 |
Why?
|
| Mannosyltransferases | 1 | 2013 | 3 | 0.120 |
Why?
|
| Adenosine Triphosphatases | 1 | 2016 | 435 | 0.120 |
Why?
|
| Hereditary Sensory and Motor Neuropathy | 1 | 2013 | 37 | 0.120 |
Why?
|
| Walker-Warburg Syndrome | 1 | 2013 | 6 | 0.120 |
Why?
|
| Global Health | 1 | 2019 | 657 | 0.120 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2016 | 244 | 0.120 |
Why?
|
| Respiratory Insufficiency | 1 | 2017 | 330 | 0.120 |
Why?
|
| Environment | 1 | 2014 | 190 | 0.120 |
Why?
|
| Mitochondrial Diseases | 1 | 2015 | 137 | 0.120 |
Why?
|
| Curriculum | 1 | 2019 | 860 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2014 | 259 | 0.110 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2015 | 592 | 0.110 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 14889 | 0.110 |
Why?
|
| Epilepsy | 1 | 2021 | 883 | 0.110 |
Why?
|
| Breast Feeding | 1 | 2014 | 239 | 0.110 |
Why?
|
| Lung Transplantation | 1 | 2017 | 359 | 0.110 |
Why?
|
| Cardiomyopathies | 2 | 2016 | 610 | 0.110 |
Why?
|
| Transcription Factors | 2 | 2019 | 5270 | 0.110 |
Why?
|
| Heart Rate | 1 | 2016 | 737 | 0.110 |
Why?
|
| Caregivers | 1 | 2018 | 677 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2020 | 1270 | 0.110 |
Why?
|
| Health Behavior | 1 | 2017 | 603 | 0.110 |
Why?
|
| Herpesvirus 4, Human | 3 | 2024 | 966 | 0.110 |
Why?
|
| Eye Movements | 1 | 2012 | 116 | 0.110 |
Why?
|
| Medication Adherence | 1 | 2017 | 492 | 0.110 |
Why?
|
| Eye | 1 | 2014 | 301 | 0.110 |
Why?
|
| Siblings | 1 | 2013 | 285 | 0.100 |
Why?
|
| Ascomycota | 2 | 2022 | 31 | 0.100 |
Why?
|
| B-Lymphocytes | 3 | 2023 | 1294 | 0.100 |
Why?
|
| Hypertension, Pulmonary | 1 | 2017 | 462 | 0.100 |
Why?
|
| Hospitalization | 2 | 2018 | 2083 | 0.100 |
Why?
|
| Treatment Outcome | 8 | 2021 | 32848 | 0.100 |
Why?
|
| Body Mass Index | 2 | 2017 | 2203 | 0.100 |
Why?
|
| DNA, Mitochondrial | 2 | 2011 | 311 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2017 | 717 | 0.100 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 435 | 0.100 |
Why?
|
| Optic Atrophy, Hereditary, Leber | 1 | 2011 | 15 | 0.100 |
Why?
|
| Methylprednisolone | 2 | 2008 | 193 | 0.100 |
Why?
|
| Leigh Disease | 1 | 2011 | 39 | 0.100 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2022 | 180 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2012 | 272 | 0.090 |
Why?
|
| Adult | 13 | 2024 | 77950 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2021 | 3343 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 1303 | 0.090 |
Why?
|
| Feeding Behavior | 1 | 2016 | 808 | 0.090 |
Why?
|
| Hospitals, Pediatric | 1 | 2014 | 773 | 0.090 |
Why?
|
| Mitochondria | 1 | 2016 | 1282 | 0.090 |
Why?
|
| Central Nervous System | 2 | 2022 | 436 | 0.090 |
Why?
|
| Diet | 1 | 2017 | 1440 | 0.090 |
Why?
|
| Guanidinoacetate N-Methyltransferase | 1 | 2008 | 9 | 0.080 |
Why?
|
| Homozygote | 3 | 2016 | 717 | 0.080 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2008 | 26 | 0.080 |
Why?
|
| Genome, Human | 1 | 2017 | 1869 | 0.080 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2008 | 105 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2013 | 1265 | 0.080 |
Why?
|
| Comorbidity | 1 | 2014 | 2352 | 0.080 |
Why?
|
| Sweden | 2 | 2017 | 70 | 0.080 |
Why?
|
| Genotype | 3 | 2023 | 4109 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2008 | 327 | 0.080 |
Why?
|
| Acute Disease | 1 | 2012 | 2422 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2014 | 806 | 0.070 |
Why?
|
| Neurologic Examination | 1 | 2007 | 245 | 0.070 |
Why?
|
| Craniofacial Abnormalities | 1 | 2008 | 239 | 0.070 |
Why?
|
| Methylphenidate | 1 | 2007 | 103 | 0.070 |
Why?
|
| Neuropsychological Tests | 2 | 2022 | 1178 | 0.070 |
Why?
|
| Interviews as Topic | 2 | 2018 | 497 | 0.070 |
Why?
|
| Genome-Wide Association Study | 3 | 2019 | 2265 | 0.070 |
Why?
|
| Central Nervous System Stimulants | 1 | 2007 | 225 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2019 | 2947 | 0.070 |
Why?
|
| Qualitative Research | 2 | 2018 | 556 | 0.070 |
Why?
|
| Autoimmunity | 2 | 2022 | 263 | 0.060 |
Why?
|
| Ubiquinone | 1 | 2005 | 37 | 0.060 |
Why?
|
| Cognition | 2 | 2022 | 968 | 0.060 |
Why?
|
| Cerebral Infarction | 1 | 2005 | 59 | 0.060 |
Why?
|
| Mutism | 1 | 2004 | 21 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 4971 | 0.060 |
Why?
|
| Cerebral Ventricles | 1 | 2005 | 98 | 0.060 |
Why?
|
| Consciousness Disorders | 1 | 2004 | 34 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2021 | 2316 | 0.060 |
Why?
|
| Qb-SNARE Proteins | 1 | 2023 | 11 | 0.060 |
Why?
|
| Logistic Models | 3 | 2018 | 3441 | 0.060 |
Why?
|
| Algorithms | 1 | 2015 | 3890 | 0.060 |
Why?
|
| Cations | 1 | 2023 | 62 | 0.060 |
Why?
|
| Risk | 2 | 2019 | 1972 | 0.060 |
Why?
|
| Neuroimaging | 2 | 2017 | 403 | 0.060 |
Why?
|
| Mevalonic Acid | 1 | 2023 | 34 | 0.060 |
Why?
|
| Fingolimod Hydrochloride | 1 | 2023 | 45 | 0.060 |
Why?
|
| Influenza A virus | 1 | 2004 | 270 | 0.060 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2023 | 44 | 0.060 |
Why?
|
| Muscle Spasticity | 1 | 2023 | 74 | 0.060 |
Why?
|
| Azathioprine | 1 | 2022 | 66 | 0.060 |
Why?
|
| Memory and Learning Tests | 1 | 2022 | 7 | 0.060 |
Why?
|
| Oligodendroglia | 1 | 2023 | 96 | 0.060 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 5687 | 0.060 |
Why?
|
| Guanosine | 1 | 2022 | 22 | 0.050 |
Why?
|
| Muscle, Skeletal | 3 | 2021 | 1270 | 0.050 |
Why?
|
| Oxidoreductases | 1 | 2023 | 171 | 0.050 |
Why?
|
| DNA Copy Number Variations | 2 | 2021 | 1516 | 0.050 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2017 | 252 | 0.050 |
Why?
|
| Cyclic GMP | 1 | 2022 | 116 | 0.050 |
Why?
|
| DNA Mutational Analysis | 2 | 2021 | 2283 | 0.050 |
Why?
|
| Demography | 1 | 2023 | 435 | 0.050 |
Why?
|
| Ultraviolet Rays | 1 | 2023 | 575 | 0.050 |
Why?
|
| Pyridostigmine Bromide | 1 | 2021 | 15 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 4821 | 0.050 |
Why?
|
| Amphotericin B | 1 | 2022 | 289 | 0.050 |
Why?
|
| Long Term Adverse Effects | 1 | 2021 | 23 | 0.050 |
Why?
|
| Mental Disorders | 1 | 2008 | 862 | 0.050 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2021 | 46 | 0.050 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2022 | 155 | 0.050 |
Why?
|
| Exons | 2 | 2016 | 1328 | 0.050 |
Why?
|
| Agammaglobulinemia | 1 | 2021 | 46 | 0.050 |
Why?
|
| Facies | 1 | 2021 | 149 | 0.050 |
Why?
|
| Age Factors | 3 | 2021 | 5377 | 0.050 |
Why?
|
| Internationality | 1 | 2022 | 208 | 0.050 |
Why?
|
| Drosophila melanogaster | 2 | 2017 | 829 | 0.050 |
Why?
|
| Nephrotic Syndrome | 1 | 2021 | 57 | 0.050 |
Why?
|
| Inheritance Patterns | 1 | 2021 | 139 | 0.050 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2021 | 67 | 0.050 |
Why?
|
| Observer Variation | 2 | 2015 | 671 | 0.050 |
Why?
|
| Antibodies | 1 | 2024 | 838 | 0.050 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2021 | 154 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2017 | 1546 | 0.050 |
Why?
|
| Cerebral Angiography | 1 | 2000 | 129 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 2195 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2023 | 546 | 0.050 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2021 | 110 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2020 | 12873 | 0.050 |
Why?
|
| Biomarkers | 3 | 2019 | 5047 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 486 | 0.040 |
Why?
|
| HLA-A3 Antigen | 1 | 2019 | 4 | 0.040 |
Why?
|
| HLA-B7 Antigen | 1 | 2019 | 4 | 0.040 |
Why?
|
| Electroencephalography | 1 | 2004 | 898 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 338 | 0.040 |
Why?
|
| Mathematical Concepts | 1 | 2018 | 13 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2020 | 249 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2021 | 267 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2012 | 3341 | 0.040 |
Why?
|
| California | 1 | 2019 | 208 | 0.040 |
Why?
|
| Charcot-Marie-Tooth Disease | 1 | 2020 | 192 | 0.040 |
Why?
|
| Base Sequence | 2 | 2016 | 4917 | 0.040 |
Why?
|
| Organizational Innovation | 1 | 2018 | 68 | 0.040 |
Why?
|
| Reading | 1 | 2018 | 81 | 0.040 |
Why?
|
| Punctures | 1 | 2018 | 104 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2023 | 1038 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2015 | 2218 | 0.040 |
Why?
|
| Water Quality | 1 | 2017 | 8 | 0.040 |
Why?
|
| Family Relations | 1 | 2018 | 88 | 0.040 |
Why?
|
| Geography, Medical | 1 | 2017 | 21 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 2016 | 6089 | 0.040 |
Why?
|
| Gene Deletion | 2 | 2016 | 1442 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 470 | 0.040 |
Why?
|
| Diet Surveys | 1 | 2017 | 117 | 0.040 |
Why?
|
| Propensity Score | 1 | 2020 | 750 | 0.040 |
Why?
|
| Influenza, Human | 1 | 2004 | 925 | 0.040 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2017 | 100 | 0.040 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2016 | 85 | 0.040 |
Why?
|
| Focus Groups | 1 | 2017 | 256 | 0.040 |
Why?
|
| Time Factors | 2 | 2021 | 12926 | 0.040 |
Why?
|
| Haplotypes | 1 | 2019 | 856 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2022 | 834 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 1493 | 0.040 |
Why?
|
| Optic Atrophy | 1 | 2016 | 46 | 0.040 |
Why?
|
| Air Pollution | 1 | 2017 | 87 | 0.030 |
Why?
|
| Arabs | 1 | 2016 | 38 | 0.030 |
Why?
|
| Animals, Genetically Modified | 1 | 2017 | 406 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2018 | 597 | 0.030 |
Why?
|
| Muscles | 1 | 2016 | 416 | 0.030 |
Why?
|
| Vegetables | 1 | 2017 | 325 | 0.030 |
Why?
|
| Golgi Apparatus | 1 | 2016 | 147 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2022 | 1879 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1945 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 677 | 0.030 |
Why?
|
| Binding Sites | 1 | 2019 | 2171 | 0.030 |
Why?
|
| Prognosis | 1 | 2012 | 21713 | 0.030 |
Why?
|
| Point Mutation | 1 | 2017 | 769 | 0.030 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2016 | 204 | 0.030 |
Why?
|
| Herpesvirus 1, Human | 1 | 2014 | 113 | 0.030 |
Why?
|
| Dystroglycans | 1 | 2013 | 15 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 4314 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 524 | 0.030 |
Why?
|
| Axons | 1 | 2016 | 403 | 0.030 |
Why?
|
| Goals | 1 | 2014 | 185 | 0.030 |
Why?
|
| Glycosylation | 1 | 2013 | 213 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2018 | 1819 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2018 | 795 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2014 | 543 | 0.030 |
Why?
|
| Animals | 4 | 2022 | 59536 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2021 | 2086 | 0.030 |
Why?
|
| Caenorhabditis elegans | 1 | 2014 | 268 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 2017 | 429 | 0.030 |
Why?
|
| Lymphoma | 1 | 2021 | 1467 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 4988 | 0.030 |
Why?
|
| Pedigree | 1 | 2016 | 1890 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2017 | 899 | 0.030 |
Why?
|
| Parents | 1 | 2018 | 998 | 0.030 |
Why?
|
| Electron Transport Chain Complex Proteins | 1 | 2011 | 25 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2015 | 561 | 0.020 |
Why?
|
| Inflammation | 1 | 2021 | 2522 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2014 | 1471 | 0.020 |
Why?
|
| Muscle Strength | 1 | 2011 | 104 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 4298 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 4053 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2016 | 1682 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 2292 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2012 | 691 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2017 | 1589 | 0.020 |
Why?
|
| Asthma | 1 | 2017 | 871 | 0.020 |
Why?
|
| Creatine | 1 | 2008 | 61 | 0.020 |
Why?
|
| Optic Neuritis | 1 | 2008 | 41 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 4233 | 0.020 |
Why?
|
| Sample Size | 1 | 2008 | 202 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 624 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2014 | 1335 | 0.020 |
Why?
|
| Serologic Tests | 1 | 2008 | 137 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2011 | 703 | 0.020 |
Why?
|
| Gadolinium | 1 | 2008 | 164 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 5159 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2008 | 421 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2012 | 2232 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 6869 | 0.020 |
Why?
|
| Neurons | 1 | 2016 | 2287 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 2588 | 0.020 |
Why?
|
| Coenzymes | 1 | 2005 | 16 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 1450 | 0.020 |
Why?
|
| Smoking | 1 | 2014 | 2440 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 3472 | 0.020 |
Why?
|
| Electron Transport | 1 | 2005 | 79 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 2005 | 92 | 0.020 |
Why?
|
| Nasal Lavage Fluid | 1 | 2004 | 19 | 0.020 |
Why?
|
| Mitochondria, Muscle | 1 | 2005 | 50 | 0.020 |
Why?
|
| Schizophrenia | 1 | 2008 | 369 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 6009 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2005 | 429 | 0.010 |
Why?
|
| Lactic Acid | 1 | 2005 | 305 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 4938 | 0.010 |
Why?
|
| Contrast Media | 1 | 2008 | 1472 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2019 | 11965 | 0.010 |
Why?
|
| Mice | 1 | 2022 | 34495 | 0.010 |
Why?
|
| Aged | 2 | 2019 | 70117 | 0.010 |
Why?
|
| Middle Aged | 2 | 2020 | 86204 | 0.010 |
Why?
|
| Texas | 1 | 2004 | 6311 | 0.010 |
Why?
|